- The objective response rate was 29 percent (4 of 22 patients)
- BeiGene and Celgene Corporation have a global strategic collaboration for the development of tislelizumab in solid tumor... read more
Pfizer Inc. (NYSE:PFE) announced on 9/... read more
MaaT Pharma announced on 9/18/19 the presentation of the analysis of MaaT Pharma’s lead biotherapeutic, MaaT013, demonstrating its drug product characteristics using MaaT Pharma’s proprietary big... read more
argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company... read more
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,